| __timestamp | Catalyst Pharmaceuticals, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 2652041 |
| Thursday, January 1, 2015 | 8597010 | 2361587 |
| Friday, January 1, 2016 | 7910260 | 4472869 |
| Sunday, January 1, 2017 | 7304399 | 5030957 |
| Monday, January 1, 2018 | 15875961 | 4988941 |
| Tuesday, January 1, 2019 | 36881187 | 5196412 |
| Wednesday, January 1, 2020 | 44233754 | 6652774 |
| Friday, January 1, 2021 | 49628000 | 18418247 |
| Saturday, January 1, 2022 | 58183000 | 24827066 |
| Sunday, January 1, 2023 | 133710000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of the pharmaceutical industry, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Opthea Limited and Catalyst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Catalyst Pharmaceuticals witnessed a staggering 2,887% increase in SG&A expenses, peaking in 2023. Opthea Limited, while more conservative, saw a 1,480% rise, with a notable spike in 2022. These trends highlight the strategic financial maneuvers each company has employed to navigate market challenges and opportunities. The absence of data for Catalyst Pharmaceuticals in 2024 suggests a potential shift or reevaluation in their financial strategy. As the industry continues to grow, understanding these financial dynamics offers invaluable insights into the operational priorities of leading pharmaceutical firms.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Opthea Limited
Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Sanofi vs Opthea Limited Trends and Insights
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Genmab A/S and Opthea Limited: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Pharming Group N.V. and Opthea Limited
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Opthea Limited vs Alpine Immune Sciences, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Opthea Limited and Mesoblast Limited
Veracyte, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared